SARS-coronavirus (SARS-CoV) and the safety of a solvent/detergent (S/D) treated immunoglobulin preparation.
Identifieur interne : 002702 ( PubMed/Curation ); précédent : 002701; suivant : 002703SARS-coronavirus (SARS-CoV) and the safety of a solvent/detergent (S/D) treated immunoglobulin preparation.
Auteurs : H F Rabenau [Allemagne] ; L. Biesert ; T. Schmidt ; G. Bauer ; J. Cinatl ; H W DoerrSource :
- Biologicals : journal of the International Association of Biological Standardization [ 1045-1056 ] ; 2005.
Descripteurs français
- KwdFr :
- MESH :
- pharmacologie : Détergents, Solvants.
- Humains, Immunoglobulines, Inactivation virale, Virus du SRAS.
English descriptors
- KwdEn :
- MESH :
- chemical , pharmacology : Detergents, Solvents.
- drug effects : SARS Virus.
- Humans, Immunoglobulins, Virus Inactivation.
Abstract
SARS-coronavirus (SARS-CoV) is a newly emerged, highly pathogenic agent that caused over 8000 human infections with nearly 800 deaths between November 2002 and September 2003. While direct person-to-person transmission via respiratory droplets accounted for most cases, other modes have not been ruled out. SARS-CoV viraemia does not seem to reach high titres, however, it has to be excluded that virus transmission may occur via blood transfusion or application of therapeutic plasma products, e.g. fresh-frozen plasma or single components derived thereof. Manufacturing processes of all plasma derivatives are required to comprise dedicated virus inactivation/removal steps. Treatment with a mixture of solvent and detergent (SD) has successfully been applied to inactivate the most members of the transfusion-relevant viruses without affecting therapeutic properties of the products. The SD treatment irreversibly disrupts the lipid envelope of viruses such as HIV, HBV, HCV, HGV and CMV. In this study we evaluated the manufacturing process of an immunoglobulin preparation (OCTAGAM, manufactured by Octapharma Pharmazeutika Produktionsges.m.b.H., Vienna, Austria) for its capacity to inactivate the SARS-CoV. Our results demonstrate that SARS-CoV was completely inactivated below the limit of detection. This was found to occur within 1 min of SD treatment.
DOI: 10.1016/j.biologicals.2005.01.003
PubMed: 15939287
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002702
Links to Exploration step
pubmed:15939287Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">SARS-coronavirus (SARS-CoV) and the safety of a solvent/detergent (S/D) treated immunoglobulin preparation.</title><author><name sortKey="Rabenau, H F" sort="Rabenau, H F" uniqKey="Rabenau H" first="H F" last="Rabenau">H F Rabenau</name><affiliation wicri:level="1"><nlm:affiliation>Institute for Medical Virology, Frankfurt am Main University Hospital Medical School, Paul Ehrlich-Str. 40, D - 60596 Frankfurt am Main, Germany. rabenau@em.uni-frankfurt.de</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Institute for Medical Virology, Frankfurt am Main University Hospital Medical School, Paul Ehrlich-Str. 40, D - 60596 Frankfurt am Main</wicri:regionArea></affiliation></author><author><name sortKey="Biesert, L" sort="Biesert, L" uniqKey="Biesert L" first="L" last="Biesert">L. Biesert</name></author><author><name sortKey="Schmidt, T" sort="Schmidt, T" uniqKey="Schmidt T" first="T" last="Schmidt">T. Schmidt</name></author><author><name sortKey="Bauer, G" sort="Bauer, G" uniqKey="Bauer G" first="G" last="Bauer">G. Bauer</name></author><author><name sortKey="Cinatl, J" sort="Cinatl, J" uniqKey="Cinatl J" first="J" last="Cinatl">J. Cinatl</name></author><author><name sortKey="Doerr, H W" sort="Doerr, H W" uniqKey="Doerr H" first="H W" last="Doerr">H W Doerr</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="RBID">pubmed:15939287</idno><idno type="pmid">15939287</idno><idno type="doi">10.1016/j.biologicals.2005.01.003</idno><idno type="wicri:Area/PubMed/Corpus">002702</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002702</idno><idno type="wicri:Area/PubMed/Curation">002702</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002702</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">SARS-coronavirus (SARS-CoV) and the safety of a solvent/detergent (S/D) treated immunoglobulin preparation.</title><author><name sortKey="Rabenau, H F" sort="Rabenau, H F" uniqKey="Rabenau H" first="H F" last="Rabenau">H F Rabenau</name><affiliation wicri:level="1"><nlm:affiliation>Institute for Medical Virology, Frankfurt am Main University Hospital Medical School, Paul Ehrlich-Str. 40, D - 60596 Frankfurt am Main, Germany. rabenau@em.uni-frankfurt.de</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Institute for Medical Virology, Frankfurt am Main University Hospital Medical School, Paul Ehrlich-Str. 40, D - 60596 Frankfurt am Main</wicri:regionArea></affiliation></author><author><name sortKey="Biesert, L" sort="Biesert, L" uniqKey="Biesert L" first="L" last="Biesert">L. Biesert</name></author><author><name sortKey="Schmidt, T" sort="Schmidt, T" uniqKey="Schmidt T" first="T" last="Schmidt">T. Schmidt</name></author><author><name sortKey="Bauer, G" sort="Bauer, G" uniqKey="Bauer G" first="G" last="Bauer">G. Bauer</name></author><author><name sortKey="Cinatl, J" sort="Cinatl, J" uniqKey="Cinatl J" first="J" last="Cinatl">J. Cinatl</name></author><author><name sortKey="Doerr, H W" sort="Doerr, H W" uniqKey="Doerr H" first="H W" last="Doerr">H W Doerr</name></author></analytic><series><title level="j">Biologicals : journal of the International Association of Biological Standardization</title><idno type="ISSN">1045-1056</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Detergents (pharmacology)</term><term>Humans</term><term>Immunoglobulins</term><term>SARS Virus (drug effects)</term><term>Solvents (pharmacology)</term><term>Virus Inactivation</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Détergents (pharmacologie)</term><term>Humains</term><term>Immunoglobulines</term><term>Inactivation virale</term><term>Solvants (pharmacologie)</term><term>Virus du SRAS ()</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Detergents</term><term>Solvents</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Détergents</term><term>Solvants</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Immunoglobulins</term><term>Virus Inactivation</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Immunoglobulines</term><term>Inactivation virale</term><term>Virus du SRAS</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">SARS-coronavirus (SARS-CoV) is a newly emerged, highly pathogenic agent that caused over 8000 human infections with nearly 800 deaths between November 2002 and September 2003. While direct person-to-person transmission via respiratory droplets accounted for most cases, other modes have not been ruled out. SARS-CoV viraemia does not seem to reach high titres, however, it has to be excluded that virus transmission may occur via blood transfusion or application of therapeutic plasma products, e.g. fresh-frozen plasma or single components derived thereof. Manufacturing processes of all plasma derivatives are required to comprise dedicated virus inactivation/removal steps. Treatment with a mixture of solvent and detergent (SD) has successfully been applied to inactivate the most members of the transfusion-relevant viruses without affecting therapeutic properties of the products. The SD treatment irreversibly disrupts the lipid envelope of viruses such as HIV, HBV, HCV, HGV and CMV. In this study we evaluated the manufacturing process of an immunoglobulin preparation (OCTAGAM, manufactured by Octapharma Pharmazeutika Produktionsges.m.b.H., Vienna, Austria) for its capacity to inactivate the SARS-CoV. Our results demonstrate that SARS-CoV was completely inactivated below the limit of detection. This was found to occur within 1 min of SD treatment.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15939287</PMID><DateCompleted><Year>2005</Year><Month>10</Month><Day>04</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1045-1056</ISSN><JournalIssue CitedMedium="Print"><Volume>33</Volume><Issue>2</Issue><PubDate><Year>2005</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Biologicals : journal of the International Association of Biological Standardization</Title><ISOAbbreviation>Biologicals</ISOAbbreviation></Journal><ArticleTitle>SARS-coronavirus (SARS-CoV) and the safety of a solvent/detergent (S/D) treated immunoglobulin preparation.</ArticleTitle><Pagination><MedlinePgn>95-9</MedlinePgn></Pagination><Abstract><AbstractText>SARS-coronavirus (SARS-CoV) is a newly emerged, highly pathogenic agent that caused over 8000 human infections with nearly 800 deaths between November 2002 and September 2003. While direct person-to-person transmission via respiratory droplets accounted for most cases, other modes have not been ruled out. SARS-CoV viraemia does not seem to reach high titres, however, it has to be excluded that virus transmission may occur via blood transfusion or application of therapeutic plasma products, e.g. fresh-frozen plasma or single components derived thereof. Manufacturing processes of all plasma derivatives are required to comprise dedicated virus inactivation/removal steps. Treatment with a mixture of solvent and detergent (SD) has successfully been applied to inactivate the most members of the transfusion-relevant viruses without affecting therapeutic properties of the products. The SD treatment irreversibly disrupts the lipid envelope of viruses such as HIV, HBV, HCV, HGV and CMV. In this study we evaluated the manufacturing process of an immunoglobulin preparation (OCTAGAM, manufactured by Octapharma Pharmazeutika Produktionsges.m.b.H., Vienna, Austria) for its capacity to inactivate the SARS-CoV. Our results demonstrate that SARS-CoV was completely inactivated below the limit of detection. This was found to occur within 1 min of SD treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rabenau</LastName><ForeName>H F</ForeName><Initials>HF</Initials><AffiliationInfo><Affiliation>Institute for Medical Virology, Frankfurt am Main University Hospital Medical School, Paul Ehrlich-Str. 40, D - 60596 Frankfurt am Main, Germany. rabenau@em.uni-frankfurt.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biesert</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Bauer</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Cinatl</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Doerr</LastName><ForeName>H W</ForeName><Initials>HW</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2005</Year><Month>04</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Biologicals</MedlineTA><NlmUniqueID>9004494</NlmUniqueID><ISSNLinking>1045-1056</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003902">Detergents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007136">Immunoglobulins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012997">Solvents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003902" MajorTopicYN="N">Detergents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007136" MajorTopicYN="Y">Immunoglobulins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012997" MajorTopicYN="N">Solvents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D038301" MajorTopicYN="Y">Virus Inactivation</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2004</Year><Month>07</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2004</Year><Month>08</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>01</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>6</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>10</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>6</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15939287</ArticleId><ArticleId IdType="pii">S1045-1056(05)00018-7</ArticleId><ArticleId IdType="doi">10.1016/j.biologicals.2005.01.003</ArticleId><ArticleId IdType="pmc">PMC7128630</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>MMWR Morb Mortal Wkly Rep. 2003 Mar 28;52(12):241-6, 248</Citation><ArticleIdList><ArticleId IdType="pubmed">12680518</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2003 May 24;361(9371):1767-72</Citation><ArticleIdList><ArticleId IdType="pubmed">12781535</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Med Microbiol Immunol. 2005 Jan;194(1-2):1-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15118911</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vox Sang. 1998;74 Suppl 1:203-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9789529</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Transfusion. 1990 Sep;30(7):591-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2402772</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Transfusion. 2003 Aug;43(8):1023-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12869106</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Transfusion. 1985 Nov-Dec;25(6):516-22</Citation><ArticleIdList><ArticleId IdType="pubmed">3934801</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2003 May 30;300(5624):1394-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12730500</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2003 May 3;361(9368):1519-20</Citation><ArticleIdList><ArticleId IdType="pubmed">12737864</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Emerg Infect Dis. 2004 Feb;10(2):210-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15030685</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Emerg Infect Dis. 2004 Jan;10(1):25-31</Citation><ArticleIdList><ArticleId IdType="pubmed">15078593</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Clin Exp Rheumatol. 1996 May-Jun;14 Suppl 15:S47-52</Citation><ArticleIdList><ArticleId IdType="pubmed">8828948</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1967-76</Citation><ArticleIdList><ArticleId IdType="pubmed">12690091</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Trends Mol Med. 2003 Aug;9(8):325-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12928032</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Transfusion. 2004 Apr;44(4):470-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15043560</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2003 May 30;300(5624):1399-404</Citation><ArticleIdList><ArticleId IdType="pubmed">12730501</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Blood. 1992 Feb 1;79(3):826-31</Citation><ArticleIdList><ArticleId IdType="pubmed">1310064</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002702 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002702 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:15939287
|texte= SARS-coronavirus (SARS-CoV) and the safety of a solvent/detergent (S/D) treated immunoglobulin preparation.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:15939287" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |